Earnings call transcript Q4 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to the Evoke Pharma's Fourth Quarter and Full Year 2022 Earnings Conference Call.

Currently, all callers have been placed in listen-only mode, and following management's prepared remarks, the call will be opened for questions. [Operator Instructions] Please be advised that today's call is being recorded.

I will now turn the call over to Daniel Kontoh-Boateng. Thank you, and you may begin.

Daniel Kontoh-Boateng

you in thank call Pharma's and today. afternoon, for Evoke participating conference Good

are Chief Matthew Gonyer, Quesenberry, me David With today Evoke's Business Commercial from Chief GIMOTI's Officer Executive EVERSANA; Evoke's and D'Onofrio, Officer. Chief Chris Officer;

now, at press we the everyone evokepharma.com. is on We issued with copy page Evoke's Relations it release well as the which today's not, Evoke's encourage should Investor a SEC. If of By report you available on of have Form earlier. release our XX-K, and also to filed read Form release is now XX-K annual as the company's website. The are press earnings available website on

that due forward-looking this its these Actual results under filings. stated Act. qualified Evoke's be Litigation on uncertainties note These business. today Reform contained including and statements statements statements. information Harbor call, or press and call XX-K making caution Form forward-looking associated Private report the is the by company's in releases to SEC that listeners those implied statements management Securities Please the We covered risks from will during cautionary filings, the and discussed annual provisions certain could on Safe forward-looking by subsequent of materially are with differ the

This the circumstances date or conference update or forward-looking this only of call any undertakes events accurate contains obligation of the time-sensitive after revise to information to conference this of Evoke as that is no live broadcast. date statements call. reflect

like to Gonyer. David would I over now Dave? that, turn to call the With

David Gonyer

joining us Thank today. you, for Daniel. Thanks everyone

Matt, metrics the turn XXXX. will far key discuss strategic operations and financials. XXXX made both progress fourth and key meeting quarter by commercial who to the in goals. events in I'll of review important start outlining over Chris then XXXX Evoke the I'll and call I'll in also and thus in

to GIMOTI year several Evoke's prescribers, in fronts. Year-over-year mentioned I release, progress new on period revenues, substantial today's and all improvements patient key growth enrollments significant a XXXX and XXXX showed fiscal XXXX. prescription compared was fills As of in

paralysis in in the marketplace. market our associated in XXXX, the to non-oral unmet need who Looking is caused by are GIMOTI's which need be cases, we that such those attention result stomach the absorbed. diabetic empty for back, the to blood story, the focused properly time to In symptoms the for the leave gastroparesis; can into the and long There stomach to treatment doesn't and clear nerve a medications be and uncontrolled from and damage food take for stomach new was value move where they sugars. is a to to intestines a proposition may high

and of are could nausea, symptoms even dehydration, made by worse. which malnutrition These accompanied and ER oral treated many too this million Far address take steps the traditional the oral to patients pain end for or often sugars. include simply million up don't with medication disease in can X bloating, have abdominal to invasive X more help symptoms; vomiting, erratic their of improve symptoms blood approximately being debilitating therapeutics or

XXXX, effective and quarter gastroparesis treating nasal fourth metoclopramide received the of for market GIMOTI outpatient GIMOTI of an approved in June diabetic is and of our to therapy FDA spray XXXX. only be the in formulation approval proven for is the gastroparesis. then non-oral FDA entered medication

we XXXX the in After establishing focused in following: unmet GIMOTI's viability by in XXXX, on addressing need, the marketplace

interactions consumer or their by conjunction with building of healthcare telehealth GoodRx, these new platform; channel pharmacy as improve include among providers, UpScriptHealth, access increasing by vitaCare, awareness the and face-to-face to access EVERSANA, accessing with partner, HCPs, and our patients wholly-owned and Medicaid sales a for coverage GIMOTI, EVERSANA for are HCPs groundbreaking commercial GIMOTI. team; and partnerships to treatment partner, this the primarily our in gastroenterologists. and state to increasing through: those we and diabetic First, And gastroparesis GIMOTI did -- a educational also

Second, of compelling progress data and we objective for succeeded in gastroparesis making standard care become toward medical presenting real-world by diabetic at treating leading GIMOTI our scientific of ultimate having forums. the

XXXX, some in ensure as And property finally, GIMOTI more available market detail as we areas on fortifying expanding only And the our is these focused potential deter enhancing in generic the provide on and will Chris specific for to possible. milestones. estate by product on competitors intellectual that long such

voiced immense been that years have the four The in place has to new treat has simply oral decades happen in we over no undertaken in does approval nothing since not upending in company gastroparesis there GIMOTI, been overnight. challenge more XX marketplace. that Until the consensus and pharmaceutical than of metoclopramide medical

College we're options. convincing that diabetic to progress recommended needed of Gastroenterology milestone though, oral instead community the very formulation important guidelines making impressive as gastroparesis by of Happily GIMOTI American spray To a nasal metoclopramide is was is This first-line in that treatment patients for and gastroparesis Evoke. GIMOTI current point, GIMOTI's treatment and therapy. the for important tablet the added new an

companies. difference news. status last shifting source is industry the GIMOTI the in-depth gastroenterology as was a we for specialty Innovators Healio betterment changing Innovators is field of a offers clinical annual and novel their Awards that And nominee for towards products event a creating an by Healio's gastroenterology. recognized among personnel GIMOTI to face Breakthrough honor under selected its field. The in information of of the award, the quo a for of Healio an in and that year, Disruptive Award movers accepted Industry are September industry gastroenterology announced the category. Disruptive role GIMOTI other hosted and the trailblazers, annual In for online was major wide from was nominated pharmaceutical

covers in the the period. leaders the available, to TD, DDW, XXXX, or from poster lives metoclopramide taking million dyskinesia, May assess for pleased largest or over opinion to key Disease of In is And study the statistics distinction tardive U.S. scientific around global a the Digestive Evoke conference real-world the using clinical world. were and The Week, incidence over claims experts and XX-year gastroenterology. to patients participated XX a which present we provided of largest for database which at

Results study of for metoclopramide information in X.X%. The with the had the with of risk The poster metoclopramide. those developing demonstrated reported than treated of to just a TD gastroparesis data update the literature taking in revealed with studies. of the And received profile patients supports current incidence stated about and gastroparesis incidence of gastroparesis metoclopramide. the TD an without and patients data safety aim medical was patients previously patients metoclopramide lower TD of -- that among treated

patients the compound important to might issue, high with -- organizations real-world help the on in By of ever revisit this largest study incidence and and supporting risk important the at this TD, gastroparesis. versus patients recognize HCPs issue of be important the benefit of we who understand risk hope

new ACG in I to recommendations, two the away recent how addition the reveal In medical guidelines mentioned first-line consensus announcements also chipping earlier. GIMOTI's at we're

or of Utilization meeting abstract in announced will abstract entitled at that this our " Healthcare be annual XXX extremely using condition. study Gastroparesis" These studies treat Resource of Care of Treated take that this key we need invasive San a of have nearly been revealed with well or place year, In with another GIMOTI the their Nasal opinion to AMCP, Antonio. Metoclopramide is week more presented Pharmacy, patients Managed taking results for the reduced The of to a received January Academy Diabetic Real-World steps Patients ER leaders. as visit an

in but Versus Utilization healthcare resource effectiveness only Metoclopramide" together that provides the Nasal another entitled treatment This accepted gastroparesis. EVERSANA, of selected for utilization Diabetic with Patients potentially from not Chicago the to as moving Treated abstract Real-World was Healthcare with abstract solution yet we data Disease X Last on Resource lecture compelling Week presentation May of "Reducing at Metoclopramide Digestive May GIMOTI for reported with a the plenary Gastroparesis in month, X. needle Oral Spray the upcoming

the important continue of For GIMOTI generate of strategy and meetings the our we'll medical beyond, remainder highlighting benefits data. of at new and to XXXX continue

vital for example property the successful and Teva strategy of brand with pharma gastroparesis. estate I is treatment prime Evoke's a litigation diabetic GIMOTI referred Next, fortifying is giant make to synonymous as recent new Pharmaceuticals. the our generic earlier, against paradigm intellectual A component enhancing to

we ANDA, of to We or certification indicated notice notice IV Teva of This from drug and Paragraph Book-listed a currently XXXX, generic last initiated And to other the patent protecting against seeking new prior lawsuit expiration rights Teva GIMOTI. the a that patents may protecting for year, infringement Teva. approval application, letter abbreviated filed FDA manufacture GIMOTI received extended had certain vigorously withdrew be Book-listed IV Orange generic Paragraph not product. pursue Last patents. as ANDA to a submitted version a an this intellectual approval property Teva expires. And and is will Orange patent GIMOTI's our its defended result, its pending until but and sell

no further filer first after by well-resourced addition, to that for XXX-day successful this receive to rights, be regulatory matter generic against strengthens and property. In defend reflects our ANDA Consequently, an we highly our firms. path eligible sought file This the typically our has GIMOTI. to larger ended outcome ANDA generic references exclusivity companies. of a intellectual is the And particularly resolve believe this strength will furthermore,

of intranasal in to treat what This title from confirms metoclopramide issued property patients II briefly gastroparesis we milestones, Moderate with USPTO of via the moderate During from December, intellectual bolstered metoclopramide severe Severe under grant route patent Phase XXXX nasal The treating Gastroparesis." XXXX, -- to of our key that utilizing the to covers patent expires "Treatment we and results methods administration. with severe we in the I'll and gastroparesis. estate In trial GIMOTI's also observed summarize. patent this a suffering Evoke moderate for

gastroparesis a Formulations patent application other issued potential This last to our which novel the patent same XXXX. in FDA allowance of nasal granted And diabetic Canadian key use patents This XXXX in the USPTO Metoclopramide," our several provides the title patents patent submitted "Nasal of of treatment. of for in Canadian a July, another XXXX. the and expire of "Nasal continuation gastroparesis. November, metoclopramide of that the entitled December by This XXXX patent expires patent in Evoke decade. Formulations for entitled Book-listed for methods previously Metoclopramide." patent two company of other property in office patent over corresponds In covers The application is the and market application under protection a would expire for filed intellectual notice the U.S. Orange treating delivery a

progress diabetic delivering far medication to concept the proprietary pathway treat and effective with pleased of We're our symptoms made associated with thus through further in gastroparesis. to establish we XXXX in naval the XXXX

goal abroad. in the opportunity our market and further to and capitalize eager are to U.S. growing this large We on

Mexico. and Our and other Canada Orange patents in intellectual property Book-listed EU, portfolio now the includes FDA patents Japan,

turning want year of over for I before operating the little fourth quarter Matt on and quarter financials take the will color call our the as to financial provide Now, key the And Chris, XXXX us a well. and to components results. through

three patients prescriptions days a slightly practice events GIMOTI quarters discount working experienced As closures fewer that first, today's patients. lastly, those to had symptom we the sales And an positive to XXXX to growth quarter weeks; higher a increase straightforward: release, to with uninsured quarters stronger circumstances, mentioned in and coincide has for offer revenue in is to in our sales as provided to and were fourth return quarter, after to during the reason sequential third fills. or revenue those it's such QX decrease of month, weather be end relief. saw slight there in which holidays though than due $XX,XXX Evoke's pharmacy of we of returns prescription tend XXXX. the this first press QX; time; also gastroparesis of levels in of The underinsured at we to the sequential the more number In holidays GIMOTI urgent net growth and product we in need saw in mix even XXXX expect X% in our three the decline

record. December XX, number January XXXX to increased approximately December reaching XXX at the HCPs through of XX% prescribers on end to XX, XXX of continues from increase, XXXX. cumulative X,XXX This the highest metric Finally, the this GIMOTI by year, prescribers at month of

as to for compared of Prescription previous finally, prescription mentioned, quarter XXX% of in by fills the increased XXXX fills X% by to And fourth the compared all XXXX. quarter. I XXXX increased

turn With over to Chris? Chris. call that, the I'll

Chris Quesenberry

Dave. you, Thank

symptoms. and in for XXXX needed EVERSANA. tremendous was add a gastroparesis as solution diabetic of GIMOTI described year what my to Evoke, a to Dave for patient relief of progress as physician year's and access last like significant I'd awareness GIMOTI to support progress

our in execute GIMOTI was with make UpScriptHealth care at for not our team EVERSANA yet is of has remain to that team strategy well this without of turns, Evoke habit and a and our will diabetic and GIMOTI the alter patients as adoption patients. at continue steady partners progress. and better. quo appropriate on and in to practitioner Our for challenges and and GIMOTI to standard made the steadfast focus to in and to healthcare the many market, improve as to patients field have remains focused we was continues gastroparesis deserve our vitaCare been and been There's inertia clinical Broadening trial priority access status suffering deepening

continued QX. prescribers our prescribers In 'XX, expand expanded doubled prescribers the Repeat metrics, ever. and QX, our quarter total XXX% by We QX, our XXXX to new growing XX% And XX%. increased over was in fourth in our best QX grew we cumulative X,XXX. nearly total XXXX, many by we new XX%. alone, new to in prescribers versus

at As Full so XXXX. for remaining patients treatment. a you'd] that did those QX. by over (ph) continuation prescribers with dispense was improvement grew, XXX% refill [And scripts our have their on excellent rate year growth dispenses, X% XX% see versus

a GIMOTI compared Refills we year-over-year. is closely watching. Lastly, QX XXX% QX grew and in refills are metric for XX% to

those Face-to-face and healthcare of and in driver practice are the XXXX era tend GIMOTI interactions adopt practice experience, total when begin providers. a evidence pattern the prescribes GIMOTI is primary to a they in a emerging most more, in It a positive We interactions see where paying prescribe be in important with The the well. provider lever. with QX as them that that practice performance is to our to has and healthcare in post-COVID approach dividends. continues was

of patient rationale were In to XXX year. the prescribing, GIMOTI programs XX% discussed, We increasing programming on experience. audience addition, the audience. benefits plan where knowledge to significant of increased educational prior total a relevant our impact our These double and reach to program. we reached a Those we conducted from year saw this case broader programs programs attendees attending last peer-to-peer and including

producing guidelines combat of as credibility by To the conversations significant guidelines has for our we quo updated and gastroparesis the our thinking, ACG the generated GIMOTI the oral summary highlighting first-line metoclopramide further leveraged added message. position to publication and and This own status of of pharmacotherapy.

and research track We also to continue to conduct patterns. patient market trial their awareness, utilization

or providers wave GIMOTI diminished Our oral of GIMOTI and side symptom improvement. confirms effects respondents symptom current feedback are they're treatment aware respondents to at seeing cited lack either options, users most XX% prior discontinued a or to XXX% improvement least roughly symptom symptom Of of were XX% some improvement. being of those survey, the we hearing who of and see current demonstrated that medications do XX% due from reported users of those last with users the were forms. any their liquid primarily not existing improvement tablet from whether gastroparesis nausea

treats to to Finally, as efficacy favorable tolerability more other on treatments. treatments attributes all compared and than related GIMOTI patients competing rated

results providers recognize there are between patients by conversations these treatments available, around what are working, how we current encouraged a is treatments therapies and still significant gap We alternative whether yet are in and these differ. and

prescription vitaCare last contributor GIMOTI, pilot, XXXX of four-month to in e-prescribe our to we switched to directly. vitaCare year, distribution distribution prescribing switch success services. was approach. of improved May after HCPs GIMOTI to significantly a Another changing allowing The

time to patient's we to prescription Additionally, the improve. a therapy, we of home, what to saw submission call the the from speed delivery of GIMOTI

primary access is GIMOTI, use. to initial When driver a hear low Reliable and we expense and their positive feedback. for get access for with to patients patients, see a ongoing out-of-pocket GIMOTI, especially

at have since the our seen With continued rates launch. to highest improve and process, vitaCare refill is the XX%, we've

Another GIMOTI is coverage for opportunity by plan. insurance

government a on prior build payers XXX launch. QX, our by of least We is Rx covered dispensers access commercial continue and one from either since quarters. approving were or with that relatively to In stable success and XX% insurance, at

congresses, which GIMOTI Dave demonstrate in to We for been which efficacy exclusive Part of were claims and pharmacy understand to of have build to the visits as physician data, real-world clinical stakeholders to clinical that which important are demographic to treatment beyond settings. and utilization of trial both us the varied studies outpatient it patients visits, safety database, affirm that providers, evidence. to access GIMOTI. and of examine healthcare further such impact our proposition a to various commitment new value These the continuing for a expanding medical on product GIMOTI visits, and we room controlled committed visits. two outlined to resources, payers, compliantly complement office submitted go These studies and on inpatient hospital accepted. data the emergency and in and like patients have allows hospital that recently link leverage data diverse setting comes

published the Now, important Week, year's new the prior studies incidence across prior Whereas in for examining the with the dyskinesia decades which metoclopramide. last survey. ago, small of Digestive XX% gastroparesis tardive update X.X% of incidence at aware to we study U.S. presented million at all an higher noticed be groundbreaking commenting the clinical of was XX-year use to conducted, physicians metoclopramide. an analysis for showed data various remains or This metoclopramide on patients lower Disease claims with patients previous much a taking studies, TD XX of rate over

publication use submit the understand several We the shortly. These on and physicians to incidence tardive data to congresses, risk-benefit information. large and assess for attention patients of plan have dyskinesia for data with of with at these updated received helping patients significant gastroparesis in metoclopramide

utilization patients the visits achieving improvement inpatient visits hospital patients office, initiation of resource months diabetic and and gastroparesis GIMOTI. initiation healthcare AMCP months six and intervals of outcome of for numerical for showed emergency gastroparesis diabetic physician all-cause and healthcare study related ER, GIMOTI before statistical six the demonstrated related upcoming significance six-month after XXX The for outpatient The fewer office study treatment, a of the for starting utilization resources and following that visits visits. explores

all cause be switching It's poster AMCP tracked half mean For to prior the should visits. metoclopramide duration about there on corporate these in a oral of for patients Pharma the important HRU, significant related to on physician website in that scientific days. statistically the coming reduction months note GIMOTI, was available or X.X to a for office Evoke

study the standard a data delivered Disease real-world plenary the months will compare Digestive session does XXX setting? compared the gastroparesis with to at for in in to how to These of insight provide of to parallel. GIMOTI on the be XXX control utilization And for next patients over care a Week, documented six oral metoclopramide were patients GIMOTI of question, mass

hospital are a an important data impact their suggest to system admitted of gastroparesis These significant of to is and healthcare with understand are having them within four on families considerable. average really diabetic patients XX the and and is XX% of the Cost studies be to days. as that the are patients times year readmitted

to excited first-in-class payers these providers share alike. and add are patient, information We they important data for and new believe will

QX In summary, are GIMOTI. quarter performance and reinforce in positive adoption of many to-date. I'd strides measures, we making improving like to our best was By

We tackled them continued with barriers to proactively have and and address urgency.

will fruit in bear believe areas to and continue those XXXX. We in value-generating invest

on focused change which in. surround patients as on for If confidence to building to remains going confidence care programs currency Our gastroparesis. is deal quo, standard in to then we the in the diabetic GIMOTI year, status with services we're GIMOTI and and we'll the have the position This information. goal with be of

financials. me over let discuss the that, to Matt turn call With to

Matthew D'Onofrio

Thanks, Chris.

turn to financials. Let's quickly

sales during $X.XX per and per approximately fourth As Dave was product the the for compared net $X.X $X.XX XXXX, $XXX,XXX XXXX, million with quarter for were the the $X.X $XXX,XXX fourth net loss approximately quarter fourth mentioned, with compared quarter share of million XXXX. or share or

$X.XX or XXXX, ended with per year compared XX, loss with XX, $X.X And December product and approximately the sales net of a December reflect the share million or XX, reverse losses was per split. million company's annual approximately million the net stock year ended for share share X-for-XX ended $X.X XXXX net the per $X.X year June XXXX, were $X.XX compared the the for net December million XXXX. $X.X loss approximately For the

GIMOTI The and service from: face-to-face year-over-year higher increased EVERSANA; partner. in sales adoption; healthcare to first-physician partner, primarily larger sales interactions prescription of was greater product increase vitaCare providers more and gastroenterologists, our with through resulting numbers physicians with prescribing their due after in net revenue physicians, increased other within sales our XXXX groups

with costs of commercialization development approximately million year. research year in GIMOTI million for prior shift quarter the decrease $X.X fourth for XXXX expenses with quarter were $XX,XXX and of to totaled of and research fourth XXXX, of full compared compared approval and expenses XXXX. June the $XX,XXX And receiving development XXXX, approximately development for Research and the selling and Evoke's of the continue for Since costs. to FDA $X.X

general fourth fourth million for the $X.X quarter $X.X and XXXX, of the were administrative XXXX. million compared of For with selling, quarter expenses approximately

commercialization For higher year XXXX, approximately the expenses $X.X primarily December development and marketing, XX, costs shifting selling, general in costs. ended approximately resulted were SG&A million research costs versus year to from sharing increase EVERSANA profit December with from costs along administrative The $X.X and XXXX. royalty XX, year-over-year ended personnel million for the and

from in the and of will the commercialization that of expect progress GIMOTI EVERSANA continue We we expenses we the sales net and future general profits to as GIMOTI. administrative attained selling, from with increase reimbursed

$X.X Total compared quarter XX, were operating year period approximately with XXXX. ended XXXX, operating full for for same December approximately compared million of approximately the year of XXXX. the of the expense million for expenses total fourth were million $XX.X $X.X the million $X.X for And XXXX with

least sales as quarter fund of XXXX, our be $X.X based equivalents current December on cash existing in the at well XXXX. believe that and to approximately and plan our operating net GIMOTI cash As equivalents sufficient third product of of our from cash operations were as We XX, million. cash future will cash flows

[ISC] the separate each These of the per or funds majority insured finally, FDIC Bank at as $XXX,XXX move to cash -- Pacific currently its Western holds insured within into up available cash of And on day (ph), is accounts sweep, and Evoke accounts. needed. accounts

we'll Operator? with questions. that, to the open And call up

Operator

sir. we'll question Company. first And with Thank Instructions] our from you, Yale & [Operator take Jen Laidlaw

open. is line Your

Yale Jen

thanks A on months the And one Good from the of the patients. the and and questions, and for year? that what there taking have quarters. is suggest more the to couple anticipate mentioned that congrats any a for XXXX? afternoon, -- that do -- first Was quarter of first you three you fourth under uninsured you that this to reduce in sign

David Gonyer

since the for we maybe far Yale, Thanks, a question. trickle haven't this so -- we but quarter, No, saw haven't. in in January, little first then,

Matthew D'Onofrio

And it, as one individuals sometimes insurer they the around -- the is year, you quantities than, move around from don't any cause of this other year-end as and reimbursement there's changes another. and to hiccups yes for in I other Matt. think know, beginning can Yes. things predictive around plans

seasonal you So, effect slight I the think of kind but of maybe there's see a otherwise. in nothing year end can that timeframe, very the

Yale Jen

Okay.

for which that? of quarters. XXXX? And maybe that cost have again, than you cost to goods the What anticipate the of is question for second goods The substantially is previous three would fourth quarter, is continue higher caused ratio related, this the

Matthew D'Onofrio

that we being prior launch was launch been that that I your question. prior that may earlier appreciate It's may have itself so, of to manufactured otherwise, -- possible increase to to had significant there. that substantially sold. been added upon wouldn't of total yes product But to some I expect view have it slightly. product it the the guess, don't we be out whack, anything expensed based this being I in as suppose considering Yale,

Yale Jen

current that will you the similar ratio probably be in cost margin the So, of goods are suggesting -- XXXX?

Matthew D'Onofrio

Yes.

Yale Jen

two And more quick ones. Okay.

reimbursement? that has the The as future, the added ACG first will I sales the impact. GIMOTI the one Does is And typically guidelines. guess, of guideline impact to as sort on to have adding positive been that well

thoughts? Just, what's your

David Gonyer

of a how step and look therapy. ACG the in very positive deal the physicians with for added to to So, for is to -- product certainly, new terms being guidelines a guidelines guidance many what

a definitely it's So, positive.

with first-line we physicians, added I to fact added to been out talking appreciate our there positioning. organization physicians As as and the the sales are to mentioned, that that field guidelines we've

a coupled It credibility that added us payers. still and confidence physician it's will with help of are remains to for generation seen to evidence building that some get we built be of lot So, in access prescribing. whether the

Yale Jen

the And here last case you that might in have have year, earlier, that do mentioned the XXXX? could question thanks answering study. IV expenses so, you in those Maybe that questions. Okay. still think is be that Does R&D I Phase -- would impact the And for guys a if last this to XXXX? that on for

David Gonyer

that the It's Yes, look FDA trial Yes, no like. working that what problem. talking to time through still about we're to trial. still taking to would agreement get

in half of any. least don't end probably have expectations first we the at XXXX, the any So, if

Yale Jen

really lot. Thanks thanks. and I great. Okay, a appreciate,

David Gonyer

Yale. Thanks,

Operator

Instructions] you. All right. Thank [Operator

further have We queue. no questions in the

Gonyer the back today's conclude like remarks. closing does to for or call portion Dave over of would that this call. So, now turn I additional any to

David Gonyer

you. Thank Great.

XXXX. GIMOTI that to I to steep growth such outlined our and and we to a still to the novel we a curve the executing our the times exhilarating we revenues on trajectory saw slight higher. forward results remainder positive is of a remind got for effort care last close look times areas both the boost that GIMOTI make gastroparesis major in standard diabetic in launch plan on and our I with humbling QX like were year saying and though reporting just strategic everyone Nonetheless, prescriptions the phase, of X% today. wanted the that just by its that product come decrease want in is for

time. you Thank for very your much

Operator

gentlemen, and today's Call and Pharma Full XXXX and concludes this Webcast. Fourth Year Ladies Earnings Evoke Quarter

your day. disconnect time, line may this wonderful have You a at and

Evoke Pharma (EVOK) 21 Mar 232022 Q4 Earnings call transcript